Amundi
REGN icon

Amundi’s Regeneron Pharmaceuticals REGN Stock Holding History

Amundi’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$632M Buy
1,013,540
+3,742
+0.4% +$2.55M 0.15% 117
2026
Q1 		$780M Buy
1,009,798
+217,892
+28% +$167M 0.21% 85
2025
Q4 		$611M Buy
791,906
+170,165
+27% +$116M 0.17% 127
2025
Q3 		$364M Sell
621,741
-275,390
-31% -$156M 0.12% 154
2025
Q2 		$491M Sell
897,131
-706,770
-44% -$394M 0.17% 117
2025
Q1 		$980M Buy
1,603,901
+52,166
+3% +$35.9M 0.36% 55
2024
Q4 		$1.14B Buy
1,551,735
+487,489
+46% +$409M 0.4% 50
2024
Q3 		$1.07B Sell
1,064,246
-72
-0% -$80.1K 0.39% 53
2024
Q2 		$1.09B Buy
1,064,318
+7,859
+0.7% +$7.62M 0.42% 50
2024
Q1 		$945M Buy
1,056,459
+142,334
+16% +$135M 0.41% 50
2023
Q4 		$825M Buy
914,125
+228,839
+33% +$188M 0.37% 56
2023
Q3 		$575M Buy
685,286
+574
+0.1% +$451K 0.28% 81
2023
Q2 		$492M Sell
684,712
-87,503
-11% -$67.5M 0.25% 99
2023
Q1 		$637M Buy
772,215
+76,780
+11% +$57.9M 0.34% 62
2022
Q4 		$494M Buy
695,435
+40,245
+6% +$29.7M 0.27% 96
2022
Q3 		$489M Buy
655,190
+100,682
+18% +$63.4M 0.29% 83
2022
Q2 		$332M Buy
554,508
+55,578
+11% +$36.1M 0.27% 96
2022
Q1 		$360M Buy
498,930
+38,600
+8% +$24.4M 0.24% 105
2021
Q4 		$284M Buy
460,330
+33,873
+8% +$20.8M 0.18% 137
2021
Q3 		$258M Buy
426,457
+225,038
+112% +$140M 0.18% 137
2021
Q2 		$113M Buy
+201,419
New +$102M 0.08% 266

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Amundi's REGN Position: Q2 2026 in Review

Amundi increased its Regeneron Pharmaceuticals (REGN) stake by 0.37% in Q2 2026, buying an estimated $2.55M and bringing the position to 1,013,540 shares worth $632M. The position accounts for 0.15% of the portfolio, ranked #117.

Amundi first reported a position in REGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $1.14B in Q4 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Amundi held 1,013,540 shares of Regeneron Pharmaceuticals worth $632M as of Q2 2026.
  • Amundi bought 3,742 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.55M.
  • Regeneron Pharmaceuticals made up 0.15% of Amundi's portfolio in Q2 2026, its #117 holding.
  • Amundi first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Amundi's Regeneron Pharmaceuticals position peaked at $1.14B in Q4 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.